Related Experiment Video
Updated: Mar 26, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Building a hit list for the fight against metastatic castration resistant prostate cancer
Jonathan D Strope1, Douglas K Price1, William D Figg1
1a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
Abstract:
Identification of genetic alterations in Metastatic Castration Resistant Prostate Cancer (mCRPC) may provide scientists and clinicians with a list of new targets for drug research and development. Recently published in Cell, Robinson et al. present the first look at genetic data from mCRPC lesions gathered over multiple years and from many institutions.
Insights
Identifying genetic changes in metastatic castration-resistant prostate cancer (mCRPC) offers new therapeutic targets. Robinson et al. analyzed mCRPC lesion data over years, revealing crucial genetic insights for drug development.
Area of Science:
- Oncology
- Genetics
- Genomics
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) remains a significant clinical challenge.
- Identifying novel therapeutic targets is crucial for improving patient outcomes in mCRPC.
- Understanding the genetic landscape of mCRPC is key to developing effective treatments.
Purpose of the Study:
- To present the first comprehensive genetic analysis of mCRPC lesions.
- To identify actionable genetic alterations for targeted drug development in mCRPC.
- To provide a foundational dataset for future mCRPC research.
Main Methods:
- Analysis of genetic data from mCRPC lesions.
- Multi-institutional data collection over several years.
- Genomic profiling of advanced prostate cancer samples.
Main Results:
- Detailed characterization of genetic alterations in mCRPC.
- Identification of potential new drug targets based on genetic mutations.
- Insights into the evolution of genetic changes in mCRPC over time.
Conclusions:
- Genetic profiling of mCRPC is essential for advancing precision medicine.
- The findings provide a valuable resource for researchers and clinicians.
- New therapeutic strategies can be developed based on identified genetic targets.
